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weight (kilograms) divided by height squared (meters).
Bioimpedance measurements of fat mass were performed at the bedside according to the standard, tetrapolar, whole body (hand-foot) technique, using a single-frequency (50-kHz) analyzer (Biodynamic-450, Biodynamics Corporation, Seattle, WA, USA). Measurements were carried out by the same operator; fat mass data were collected and analyzed by the specific formulas supplied by the manufacturer. 10 
Biochemical Investigations
Fasting blood samples taken from each subject were immediately centrifuged at 3,000 × g for 10 min for biochemical study. The serum was stored at 4°C for examination within 1 h of collection. Serum levels of creatinine (Cre), fasting glucose, total cholesterol, triglycerides (TG), high-density lipoproteincholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), albumin, globulin, and high-sensitivity C-reactive protein (hs-CRP) were measured using an autoanalyzer (COBAS Integra 800, Roche Diagnostics, Basel, Switzerland).
Serum FABP4 (SPI-BIO, Montigny le Bretonneux, France) levels were measured using a commercially available enzyme immunosassay. 10, 11 
MetS and its Components
The prevalence of MetS was defined using the International 
FABP4 and MetS in CAD
Diabetes Federation definition. 12 Subjects were classified as having MetS if they had central (abdominal) obesity with a waist circumference ≥90 cm (men) or ≥80 cm (women) (Chinese criteria), and 2 or more of the following criteria: fasting serum glucose ≥110 mg/dl, TG ≥150 mg/dl, HDL-C <40 mg/dl in men or <50 mg/dl in women, or blood pressure ≥130/85 mmHg. The use of antihypertensive medication was considered as high blood pressure in this analysis. Type 2 diabetes was determined according to World Health Organization criteria. 13 A person was regarded as diabetic if the fasting plasma glucose was ≥126 mg/dl or the 2-h glucose during an oral glucose tolerance test was ≥200 mg/dl or diabetes medication (oral or insulin) was being taken.
Statistical Analysis
Data are expressed as mean ± standard deviation and tested for normal distribution by Kolmogorov-Smirnov statistics. Categorical variables were analyzed by the chi-square test.
Comparisons between patients were performed using Student's independent t-test (2-tailed) for normally distributed data or the Mann-Whitney U test for parameters that presented with non-normal distribution (fasting glucose, hs-CRP, Cre, and FABP4). Clinical variables that correlated with serum FABP4 levels in the CAD patients were evaluated by univariate linear regression analyses. The significance of differences in the FABP4 level between groups (number of vessels occluded because of CAD and number of MetS criteria) was analyzed by the Kruskal-Wallis analysis of variance test. Variables that were significantly associated with FABP4 in CAD patients were tested for independency in a multivariate forward stepwise regression analysis. Data were analyzed using SPSS for Windows (version 13.0; SPSS Inc, Chicago, IL, USA). A P-value <0.05 was considered statistically significant.
Results
The clinical and laboratory characteristics of the CAD patients are presented in Table 1 . Medical histories included diabetes (n=36; 36.7%), hypertension (n=77; 78.6%), and hyperlipidemia (n=59; 60.2%). Drugs being used included angiotensinreceptor blockers (ARBs; n=34; 34.7%), angiotensin-converting enzyme inhibitors (ACEIs; n=26; 26.5%), calcium-channel blockers (CCBs; n=18; 18.4%), β-blockers (n=59; 60.2%), thiazide (n=22; 22.4%) and statins (n=56; 57.1%).
The clinical characteristics and fasting serum levels of FABP4 of the 98 CAD patients are presented in Table 2 : 50 patients (51.0%) had MetS and 48 (49.0%) did not. CAD patients who had MetS had higher serum fasting levels of FABP4 than those without MetS (P=0.037). FABP4 levels did not differ statistically by sex, age, diabetes, hypertension, hyperlipidemia, ARBs, ACEIs, CCBs, β-blockers, thiazide or statins.
Fasting serum levels of FABP4 according to the number of stenotic coronary arteries and MetS diagnostic criteria are presented in Figures 1 and 2 . There was a tendency for increased fasting levels of FABP4 as the number of stenotic Table 3 . Body fat mass (R=0.234; P=0.020) and the levels of TG (R=0.348; P<0.001) and LDL-C (R=0.217; P=0.032) positively correlated with fasting serum levels of FABP4, whereas the level of HDL-C (R=−0.243; P=0.016) showed a negative correlation.
Multivariate forward stepwise linear regression analysis of the variables that were significantly associated with the fasting serum levels of FABP4 among the CAD patients (body fat mass, TG, HDL-C, LDL-C) showed that the level of TG (β=0.348, R 2 =0.121, P<0.001) was the independent predictor.
Discussion
The results of our study show that the fasting level of FABP4 positively associated with MetS in CAD patients, among whom the serum levels of FABP4 correlated with a number of MetS criteria and TG was an independent predictor.
MetS is a constellation of physical and laboratory abnormalities, including hypertension, hyperglycemia, hyperlipidemia, and abdominal obesity. 12 Visceral fat accumulation may contribute to the development of CAD through progression of insulin resistance and an increase in apo-B-containing lipoproteins and small-sized LDL-C. 14 However, another study noted that lower levels of HDL-C may be most useful for predicting CAD independent of other metabolic markers such as adiponectin, visceral fat or present medication. 15 MetS constitutes a major health problem in the West and is estimated to affect at least 20% of the adult population. 16 Recent studies have also demonstrated that MetS is a significant risk factor for cardiovascular disease and mortality in the general population; 4, 5 it is also predicted that MetS will increase the all-cause and cardiac mortality, especially after 10 years, in non-diabetic patients undergoing coronary artery bypass grafting. 17 The overall prevalence of MetS in CAD patients is between 45.1% and 65.5%. 7, 18, 19 In our study it was 50.1%, which is almost the same as reported by other studies of CAD patients. 7, 18 FABP4 is a major cytoplasmic protein that is involved in the regulation of lipid metabolism and is expressed abundantly in mature adipocytes and activated macrophages. 2, 20 It binds fatty acid ligands with high affinity and functions in intracellular fatty acid trafficking, regulation of lipid metabolism, and modulation of gene expression. 1, 21 The serum level of FABP4 increases in patients with MetS, 22, 23 and predicts the development of MetS. 8 Our study also found that CAD patients with MetS had higher fasting serum levels of FABP4. A recent study noted that FABP4 levels increase significantly as the number of stenotic coronary vessels increases from 0 to 3. 18 We also noted a tendency for increasing fasting levels of FABP4 as the number of stenotic coronary vessels increased in the CAD patients; however, there was no statistically significant difference between the number of stenotic vessels and serum levels of FABP4. Moreover, our study also noted a tendency for increasing fasting levels of FABP4 as the number of diagnostic criteria for MetS increased. The highest fasting level of FABP4 occurred with a combination of 5 MetS diagnostic criteria and the lowest value was noted in patients with none.
Individuals with a fatty acid-binding protein aP2 variant have lower levels of TG and a reduced risk of coronary heart disease and obesity-induced type 2 diabetes. 24 Serum levels of FABP4 positively correlate with TG and negatively correlate with HDL-C; 21, 22 the fasting level of TG has been identified as a significant risk factor for CAD in middle-aged Japanese men. 25 In patients with diabetes, FABP4 positively correlates with plasma levels of TG, apolipoprotein C-III, and all the components of TG-rich lipoproteins, including very low-density lipoprotein (VLDL) TG, VLDL-C, and VLDL apoB. 26 Cabré et al also noted that plasma levels of FABP4 are increased in familial combined hyperlipidemia, 27 which manifests as increased production of TG-rich lipoproteins, mainly liver-derived VLDL, with the ensuing hyperlipidemia characterized by increased plasma levels of both TG and cholesterol. 28 Our study of CAD patients also noted that serum levels of TG and LDL-C positively correlated with the fasting serum level of FABP4, and that HDL-C had a negative correlation. Some studies have noted that serum levels of FABP4 positively correlate with central adiposity and fasting glucose, 21,22 but we did not find such as association. FABP4 is expressed in adipocytes, 1,2 but our study also showed that body fat mass positively correlates with the fasting serum level of FABP4. Multivariate forward stepwise linear regression analysis of the significant variables showed that in our study the TG level was the independent predictor of the fasting serum level of FABP4.
Pharmacological interventions have been shown to influence serum levels of FABP4 in humans; 3 months' treatment with atorvastatin in hyperlipidemic non-diabetic subjects substantially decreased the serum FABP4 value. 29 Another study of subjects with type 2 diabetes found no difference in the levels of FABP4 in statin-treated subjects, but reported increased levels in a thiazolidinedione-treated subgroup. 30 The FABP4 level was lower in subjects taking aspirin, and higher in subjects taking statins and anti-hypertensive drugs. 18 Our results did not show a relationship between statins, peroxisome proliferator-activated receptor γ agonists or other drugs (ARBs, ACEIs, CCBs or thiazide diuretics) and the serum level of FABP4. Further studies are required to elucidate the relationship between medications and the level of FABP4 in CAD patients.
Study Limitations
Firstly, this study was cross-sectional, so our findings should be investigated in long-term prospective studies before a causal relationship between the serum level of FABP4 and MetS in CAD patients can be established. Secondly, we did not have data for serum levels of insulin or the incidence of insulin resistance. Some studies have noted that the level of FABP4 positively correlates with insulin resistance or the fasting serum level of insulin. 21, 22 Another limitation is that we did not assess the relationship between FABP4 and MetS among patients without CAD and did not compare them with the CAD group. Further studies are needed to show the association of MetS and serum FABP4 level in patients with and without CAD.
Conclusion
We found a positive association between the circulating FABP4 and MetS in CAD fasting level of FABP4 and MetS among CAD patients. Serum FABP4 levels correlated with the number of MetS criteria and TG was an independent predictor in this cohort.
